Alto Neuroscience, Inc. (ANRO) — SEC Filings

Latest SEC filings for Alto Neuroscience, Inc. (ANRO), explained in plain English.

Sentiment Overview: 3 bullish, 1 bearish, 26 neutral, 1 mixed

Recent Filings (31)

• Alto Narrows Quarterly Loss, Boosts Capital with $49.9M Private Placement — 10-Q · 2025-11-12T00:00:00.000Z [mixed] Risk: medium
  Alto Neuroscience, Inc. (ANRO) reported a net loss of $14.181 million for the three months ended September 30, 2025, an improvement from the $16.783 million net
• Alto Neuroscience 8-K: Agreements, Sales, and Other Events — 8-K · 2025-10-20T00:00:00.000Z [neutral] Risk: medium
  Alto Neuroscience, Inc. filed an 8-K on October 20, 2025, reporting on events as of October 19, 2025. The filing indicates the entry into and termination of mat
• Alto Neuroscience Losses Widen Amid Stable R&D Spend — 10-Q · 2025-08-13T00:00:00.000Z [bearish] Risk: high
  Alto Neuroscience, Inc. reported a net loss of $17.706 million for the three months ended June 30, 2025, an increase from $16.030 million for the same period in
• Alto Neuroscience Announces Director Changes — 8-K · 2025-07-08T00:00:00.000Z [neutral] Risk: low
  Alto Neuroscience, Inc. announced on July 3, 2025, the departure of Director Dr. David Kupfer and the appointment of Dr. Michael R. Liebowitz as a new director.
• Alto Neuroscience Files 8-K Report — 8-K · 2025-06-26T00:00:00.000Z [neutral] Risk: low
  On June 26, 2025, Alto Neuroscience, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No specific
• Alto Neuroscience Files 8-K — 8-K · 2025-06-03T00:00:00.000Z [neutral] Risk: medium
  On May 31, 2025, Alto Neuroscience, Inc. entered into a material definitive agreement. The company also reported on unregistered sales of equity securities and
• Alto Neuroscience Files Q1 2025 10-Q — 10-Q · 2025-05-14T00:00:00.000Z [neutral] Risk: medium
  Alto Neuroscience, Inc. filed its quarterly report for the period ending March 31, 2025. The company, focused on pharmaceutical preparations, reported its finan
• Alto Neuroscience Files 2025 Proxy Statement — DEF 14A · 2025-04-01T00:00:00.000Z [neutral] Risk: low
  Alto Neuroscience, Inc. filed its definitive proxy statement on April 1, 2025, for its annual meeting. The filing covers the fiscal year ending December 31, 202
• 10-K Filing — 10-K · 2025-03-20T00:00:00.000Z [neutral]
• Alto Neuroscience Files 8-K — 8-K · 2025-02-12T00:00:00.000Z [neutral] Risk: low
  Alto Neuroscience, Inc. filed an 8-K on February 12, 2025, reporting other events and financial statements. The filing does not contain specific financial figur
• Alto Neuroscience Files 8-K with Definitive Agreement Update — 8-K · 2025-02-03T00:00:00.000Z [neutral] Risk: medium
  Alto Neuroscience, Inc. filed an 8-K on February 3, 2025, reporting an entry into a material definitive agreement and providing updates on its results of operat
• Alto Neuroscience Files 8-K: Material Agreement & Equity Sales — 8-K · 2025-01-16T00:00:00.000Z [neutral] Risk: medium
  On January 13, 2025, Alto Neuroscience, Inc. entered into a material definitive agreement, creating a direct financial obligation. The company also reported unr
• SC 13G Filing — SC 13G · 2024-11-14T00:00:00.000Z [neutral]
• SC 13G/A Filing — SC 13G/A · 2024-11-14T00:00:00.000Z [neutral]
• Alto Neuroscience 10-Q Filing: Q3 2024 Update — 10-Q · 2024-11-12T00:00:00.000Z [neutral] Risk: medium
  Alto Neuroscience, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported its financial results and provided updates on its clinical
• SC 13G Filing — SC 13G · 2024-11-12T00:00:00.000Z [neutral]
• SC 13G Filing — SC 13G · 2024-11-08T00:00:00.000Z [neutral]
• Alto Neuroscience Files 8-K Report — 8-K · 2024-10-22T00:00:00.000Z [neutral] Risk: low
  On October 22, 2024, Alto Neuroscience, Inc. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibits." No speci
• SC 13G Filing — SC 13G · 2024-10-21T00:00:00.000Z [neutral]
• Alto Neuroscience Files Q2 2024 10-Q — 10-Q · 2024-08-13T00:00:00.000Z [neutral] Risk: medium
  Alto Neuroscience, Inc. filed its 10-Q for the period ending June 30, 2024. The company, focused on pharmaceutical preparations, reported financial data for the
• Alto Neuroscience Files 8-K: Material Agreement & Equity Sales — 8-K · 2024-07-29T00:00:00.000Z [neutral] Risk: medium
  On July 24, 2024, Alto Neuroscience, Inc. entered into a Material Definitive Agreement, creating a direct financial obligation. The company also reported on unr
• Alto Neuroscience Appoints New Chief Medical Officer — 8-K · 2024-05-21T00:00:00.000Z [neutral] Risk: medium
  Alto Neuroscience, Inc. announced on May 21, 2024, the appointment of Dr. Jonathan F. Miller as Chief Medical Officer. Dr. Miller, previously a Senior Medical D
• Alto Neuroscience Files Q1 2024 10-Q Report — 10-Q · 2024-05-14T00:00:00.000Z [neutral] Risk: medium
  Alto Neuroscience, Inc. filed its quarterly report for the period ending March 31, 2024. The company, operating in the pharmaceutical preparations sector, repor
• SC 13G Filing — SC 13G · 2024-03-29T00:00:00.000Z [neutral]
• Alto Neuroscience Files 2023 Annual Report — 10-K · 2024-03-21T00:00:00.000Z [neutral] Risk: low
  Alto Neuroscience, Inc. filed its 2023 annual report on Form 10-K on March 21, 2024. The company, incorporated in Delaware, is focused on pharmaceutical prepara
• Alto Neuroscience Appoints New CMO, Adds Director — 8-K · 2024-03-11T00:00:00.000Z [neutral] Risk: medium
  Alto Neuroscience, Inc. announced on March 8, 2024, the appointment of Dr. David Kupfer as Chief Medical Officer and the election of Ms. Jennifer McNeley to its
• Alpha Wave Global Takes 5.0% Stake in Alto Neuroscience — SC 13G · 2024-02-09T00:00:00.000Z [bullish] Risk: low
  Alpha Wave Global, LP, a Delaware-based investment firm, has reported a significant stake in Alto Neuroscience, Inc. (NASDAQ: ALTO), a pharmaceutical preparatio
• Point72 Asset Management Takes 5.1% Stake in Alto Neuroscience — SC 13G · 2024-02-07T00:00:00.000Z [bullish] Risk: low
  Point72 Asset Management, L.P. has disclosed a significant stake in Alto Neuroscience, Inc., acquiring shared voting and dispositive power over 1,025,000 shares
• Alto Neuroscience Common Stock Lists on NYSE Under ANRO — 8-K · 2024-02-06T00:00:00.000Z [bullish]
  Alto Neuroscience, Inc. filed an 8-K on February 6, 2024, to report that its common stock, with a par value of $0.0001 per share, is now registered on The New Y
• Alto Neuroscience Amends S-1, Nears Public Offering — S-1/A · 2024-01-29T00:00:00.000Z [neutral]
  Alto Neuroscience, Inc. filed an S-1/A on January 29, 2024, which is an amendment to their initial S-1 registration statement (No. 333-276495) for a proposed pu
• Alto Neuroscience Files S-1 for IPO, Eyes Public Market Debut — S-1 · 2024-01-12T00:00:00.000Z [neutral]
  Alto Neuroscience, Inc. filed an S-1 registration statement on January 12, 2024, for a proposed initial public offering (IPO) of its securities. The company, ba